Welcome to our dedicated page for MoonLake Immunotherapeutics news (Ticker: MLTX), a resource for investors and traders seeking the latest updates and insights on MoonLake Immunotherapeutics stock.
MoonLake Immunotherapeutics (NASDAQ: MLTX) generates frequent news as it advances sonelokimab, an investigational Nanobody® targeting IL‑17A and IL‑17F, through late-stage clinical development in inflammatory skin and joint diseases. Company updates often center on clinical trial milestones, regulatory interactions, and financing activities that shape the outlook for its lead asset.
News items include detailed readouts from key trials such as the Phase 3 VELA program in adult hidradenitis suppurativa (HS), the adolescent VELA‑TEEN trial, the Phase 3 IZAR program in psoriatic arthritis (PsA), and Phase 2 studies like LEDA in palmoplantar pustulosis (PPP) and S‑OLARIS in axial spondyloarthritis (axSpA). Releases describe endpoints such as HiSCR75 in HS, ACR50 in PsA, PPPASI in PPP, and report on safety profiles, patient-reported outcomes and long-term follow-up analyses.
Investors following MLTX news will also see regulatory updates, including feedback from the U.S. Food and Drug Administration on the clinical evidence package for HS and guidance related to a planned Biologics License Application for sonelokimab. Financial communications, such as quarterly and annual results, equity offerings and a non-dilutive term loan facility, provide context on MoonLake’s ability to fund its clinical programs and preparations for potential commercialization.
In addition, MoonLake issues announcements about Capital Markets Days, R&D-focused webcasts and presentations at medical and investor conferences, where management discusses trial designs, baseline characteristics, interim data and anticipated milestones. This news page aggregates such releases so readers can review the evolving clinical and corporate narrative around sonelokimab and MoonLake’s broader inflammatory disease portfolio.
MoonLake Immunotherapeutics (NASDAQ:MLTX) reported its Q3 2022 financial results, highlighting a cash position of $83.5 million, providing a runway into 2H 2024. The global trial of sonelokimab for Hidradenitis Suppurativa continues to meet recruitment goals, with primary endpoint data expected mid-2023. Additionally, the Psoriatic Arthritis trial received FDA clearance and is on schedule. R&D expenses decreased to $9 million from $11.4 million, while the net loss narrowed to $14.7 million compared to the previous quarter.
MoonLake Immunotherapeutics has received FDA clearance to initiate a global Phase 2 clinical study for its investigational Nanobody® sonelokimab in patients with active psoriatic arthritis. The study aims to enroll around 200 patients to evaluate the drug's efficacy and safety against a placebo, with adalimumab as a reference. This milestone follows the completion of prior clinical trials and aims to assess significant outcomes related to this complex disease.
MoonLake Immunotherapeutics has signed a Master Development Services Agreement with Vetter Pharma International. This partnership will focus on the aseptic filling of syringes with sonelokimab, an investigational Nanobody® targeting inflammatory diseases. The manufacturing studies are set to conclude, with clinical Good Manufacturing Practice batches expected by Q4 2022. This agreement strengthens the supply chain for sonelokimab, aimed at conditions like hidradenitis suppurativa and psoriatic arthritis, significantly impacting patients in need.
MoonLake Immunotherapeutics has commenced a Phase 2 clinical trial for sonelokimab, a novel Nanobody® aimed at treating moderate-to-severe hidradenitis suppurativa (HS). This trial is significant as it uses the HiSCR75 endpoint, a ≥75% reduction in total abscess and inflammatory nodule count. The global trial will include over 200 patients, comparing sonelokimab to placebo and adalimumab. This milestone follows the FDA's approval of the trial protocol, with expected completion by the end of 2023. Sonelokimab targets IL-17 dimers, potentially improving outcomes for HS patients.